{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,24]],"date-time":"2025-11-24T09:55:29Z","timestamp":1763978129912,"version":"3.37.3"},"reference-count":22,"publisher":"Oxford University Press (OUP)","issue":"Supplement_1","license":[{"start":{"date-parts":[[2020,4,1]],"date-time":"2020-04-01T00:00:00Z","timestamp":1585699200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"DOI":"10.13039\/100004330","name":"GlaxoSmithKline","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004330","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,4,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>To determine antibiotic susceptibility of Streptococcus pneumoniae and Haemophilus influenzae isolates from community-acquired respiratory tract infections (CA-RTIs) collected in 2015\u201317 from Kuwait, Lebanon and Saudi Arabia.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>MICs were determined by CLSI broth microdilution and susceptibility was assessed using CLSI, EUCAST (dose-specific) and pharmacokinetic\/pharmacodynamic (PK\/PD) breakpoints.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>A total of 139 S. pneumoniae isolates were collected from four centres in Kuwait, Lebanon and Saudi Arabia in 2015\u201317 and 55 H. influenzae isolates were collected and analysed from Saudi Arabia over the same time period. Pneumococci from all three countries were commonly non-susceptible to penicillin based on CLSI oral or low-dose IV penicillin using EUCAST breakpoints (39% in Kuwait to 57.1% in Lebanon) but by CLSI IV and EUCAST high-dose breakpoints most isolates were susceptible (\u223c90% in Kuwait and Saudi Arabia, and 100% in Lebanon). Isolates from Lebanon were highly susceptible to most other antibiotics (&amp;gt;90%) except cefaclor, oral cefuroxime and cefpodoxime (EUCAST breakpoints only). Overall, susceptibility was significantly lower in Kuwait and Saudi Arabia than Lebanon. Although all H. influenzae isolates (Saudi Arabia only) were \u03b2-lactamase negative, 3.6% and 12.7% were ampicillin resistant by CLSI and EUCAST breakpoints, respectively. Otherwise susceptibility was high in H. influenzae. The application of different EUCAST breakpoints for low and higher doses for some of the antibiotics (amoxicillin, amoxicillin\/clavulanic acid, ampicillin, penicillin, ceftriaxone, clarithromycin, erythromycin, levofloxacin and trimethoprim\/sulfamethoxazole) allowed, for the first time in a SOAR study, the effect of raising the dosage on susceptibility to be quantified.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Relatively low antibiotic susceptibility was observed in S. pneumoniae from Kuwait and Saudi Arabia in contrast to Lebanon, where rates of susceptibility were generally higher. Isolates of H. influenzae from Saudi Arabia were susceptible to most antibiotics. These factors are important in decision making for empirical therapy of CA-RTIs.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/jac\/dkaa084","type":"journal-article","created":{"date-parts":[[2020,3,16]],"date-time":"2020-03-16T20:33:21Z","timestamp":1584390801000},"page":"i60-i75","source":"Crossref","is-referenced-by-count":6,"title":["Results from the Survey of Antibiotic Resistance (SOAR) 2015\u201317 in the Middle East (Kuwait, Lebanon and Saudi Arabia): data based on CLSI, EUCAST (dose-specific) and pharmacokinetic\/pharmacodynamic (PK\/PD) breakpoints"],"prefix":"10.1093","volume":"75","author":[{"given":"D","family":"Torumkuney","sequence":"first","affiliation":[{"name":"GlaxoSmithKline, 980 Great West Road, Brentford, Middlesex TW8 9GS, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E","family":"Mokaddas","sequence":"first","affiliation":[{"name":"Microbiology Department, Faculty of Medicine, Kuwait University, Jabrya, Kuwait"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A","family":"Jiman-Fatani","sequence":"first","affiliation":[{"name":"Department of Medical Microbiology and Parasitology, Faculty of Medicine, King Abdulaziz University, Jeddah, Saudi Arabia and Clinical and Molecular Microbiology Laboratory, King Abdulaziz University Hospital, Jeddah, Saudi Arabia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A","family":"Ageel","sequence":"first","affiliation":[{"name":"Pathology and Clinical Laboratory Medicine Administration, King Fahad Medical City, Dhabab Street, PO Box 59046 Riyadh, Saudi Arabia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Z","family":"Daoud","sequence":"first","affiliation":[{"name":"Faculty of Medicine and Medical Sciences, University of Balamand, Al Koura, Tripoli, Lebanon"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Y","family":"Bouferraa","sequence":"first","affiliation":[{"name":"Faculty of Medicine and Medical Sciences, University of Balamand, Al Koura, Tripoli, Lebanon"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M B","family":"Zerdan","sequence":"first","affiliation":[{"name":"Faculty of Medicine and Medical Sciences, University of Balamand, Al Koura, Tripoli, Lebanon"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"I","family":"Morrissey","sequence":"first","affiliation":[{"name":"IHMA Europe S\u00e0rl, Route de l\u2019Ile-au-Bois 1A, 1870 Monthey\/VS, Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2020,4,21]]},"reference":[{"key":"2020042620060209900_dkaa084-B1","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1080\/17476348.2019.1562339","article-title":"The burden of community-acquired bacterial pneumonia in the era of antibiotic resistance","volume":"13","author":"Peyrani","year":"2019","journal-title":"Expert Rev Respir Med"},{"key":"2020042620060209900_dkaa084-B2","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1080\/17476348.2019.1555040","article-title":"Epidemiology of lower respiratory tract infections in adults","volume":"13","author":"Feldman","year":"2019","journal-title":"Expert Rev Respir Med"},{"key":"2020042620060209900_dkaa084-B3","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1097\/MCC.0000000000000550","article-title":"Community-acquired pneumonia as an emergency condition","volume":"24","author":"Cill\u00f3niz","year":"2018","journal-title":"Curr Opin Crit Care"},{"key":"2020042620060209900_dkaa084-B4","first-page":"e000214","article-title":"The return of Pfeiffer\u2019s bacillus: rising incidence of ampicillin resistance in Haemophilus influenzae","volume":"4","author":"Heinz","year":"2018","journal-title":"Microb Genom"},{"year":"2018","key":"2020042620060209900_dkaa084-B5"},{"year":"2019","key":"2020042620060209900_dkaa084-B6"},{"year":"2019","key":"2020042620060209900_dkaa084-B7"},{"key":"2020042620060209900_dkaa084-B8","first-page":"1","article-title":"Antimicrobial treatment guidelines for acute bacterial rhinosinusitis","volume":"130 Suppl 1","author":"Anon","year":"2004","journal-title":"Otolaryngol Head Neck Surg"},{"key":"2020042620060209900_dkaa084-B9","doi-asserted-by":"crossref","first-page":"i45","DOI":"10.1093\/jac\/dkw064","article-title":"Results from the Survey of Antibiotic Resistance (SOAR) 2011-13 in the Gulf States","volume":"71 Suppl 1","author":"Jamsheer","year":"2016","journal-title":"J Antimicrob Chemother"},{"key":"2020042620060209900_dkaa084-B10","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1099\/jmm.0.000503","article-title":"Molecular mechanisms and epidemiology of resistance in Streptococcus pneumoniae in the Middle East region","volume":"66","author":"El Moujaber","year":"2017","journal-title":"J Med Microbiol"},{"key":"2020042620060209900_dkaa084-B11","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.ijid.2016.03.010","article-title":"Surveillance of antimicrobial resistance in Lebanese hospitals: retrospective nationwide compiled data","volume":"46","author":"Chamoun","year":"2016","journal-title":"Int J Infect Dis"},{"key":"2020042620060209900_dkaa084-B12","doi-asserted-by":"crossref","first-page":"G11","DOI":"10.1016\/j.vaccine.2012.07.020","article-title":"Epidemiologic characteristics, serotypes, and antimicrobial susceptibilities of invasive Streptococcus pneumoniae isolates in a nationwide surveillance study in Lebanon","volume":"30 Suppl 6","author":"Hanna-Wakim","year":"2012","journal-title":"Vaccine"},{"author":"Sievers","key":"2020042620060209900_dkaa084-B13"},{"key":"2020042620060209900_dkaa084-B14","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.jiph.2010.02.003","article-title":"Antimicrobial resistance in clinical isolates of Streptococcus pneumoniae in a tertiary hospital in Kuwait, 1997-2007: implications for empiric therapy","volume":"3","author":"Johny","year":"2010","journal-title":"J Infect Public Health"},{"key":"2020042620060209900_dkaa084-B15","doi-asserted-by":"crossref","first-page":"G37","DOI":"10.1016\/j.vaccine.2012.10.061","article-title":"Impact of pneumococcal conjugate vaccines on burden of invasive pneumococcal disease and serotype distribution of Streptococcus pneumoniae isolates: an overview from Kuwait","volume":"30 Suppl 6","author":"Mokaddas","year":"2012","journal-title":"Vaccine"},{"key":"2020042620060209900_dkaa084-B16","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.jegh.2015.08.002","article-title":"Epidemiology of invasive pneumococcal disease in Saudi Arabian children younger than 5 years of age","volume":"6","author":"Almazrou","year":"2016","journal-title":"J Epidemiol Glob Health"},{"key":"2020042620060209900_dkaa084-B17","doi-asserted-by":"crossref","first-page":"G32","DOI":"10.1016\/j.vaccine.2012.07.030","article-title":"Antibiotic resistance and serotype distribution of invasive pneumococcal diseases before and after introduction of pneumococcal conjugate vaccine in the Kingdom of Saudi Arabia (KSA)","volume":"30 Suppl 6","author":"Shibl","year":"2012","journal-title":"Vaccine"},{"key":"2020042620060209900_dkaa084-B18","doi-asserted-by":"crossref","first-page":"210","DOI":"10.3343\/alm.2014.34.3.210","article-title":"Distribution of serotypes and antibiotic susceptibility patterns among invasive pneumococcal diseases in Saudi Arabia","volume":"34","author":"Al-Sheikh","year":"2014","journal-title":"Ann Lab Med"},{"key":"2020042620060209900_dkaa084-B19","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1186\/s12889-018-6088-z","article-title":"\u201cAntibiotics kill things very quickly\u201d\u2014consumers\u2019 perspectives on non-prescribed antibiotic use in Saudi Arabia","volume":"18","author":"Alhomoud","year":"2018","journal-title":"BMC Public Health"},{"key":"2020042620060209900_dkaa084-B20","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1093\/jac\/45.2.191","article-title":"The Alexander Project 1996-1997: latest susceptibility data from this international study of bacterial pathogens from community-acquired lower respiratory tract infections","volume":"45","author":"Felmingham","year":"2000","journal-title":"J Antimicrob Chemother"},{"key":"2020042620060209900_dkaa084-B21","doi-asserted-by":"crossref","first-page":"R84","DOI":"10.1186\/cc12705","article-title":"Meropenem and piperacillin\/tazobactam prescribing in critically ill patients: does augmented renal clearance affect pharmacokinetic\/pharmacodynamic target attainment when extended infusions are used","volume":"17","author":"Carlier","year":"2013","journal-title":"Crit Care"},{"key":"2020042620060209900_dkaa084-B22","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1007\/s40262-018-0643-8","article-title":"Target-controlled continuous infusion for antibiotic dosing: proof-of-principle in an in-silico vancomycin trial in intensive care unit patients","volume":"57","author":"Colin","year":"2018","journal-title":"Clin Pharmacokinet"}],"container-title":["Journal of Antimicrobial Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jac\/article-pdf\/75\/Supplement_1\/i60\/33121573\/dkaa084.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/jac\/article-pdf\/75\/Supplement_1\/i60\/33121573\/dkaa084.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,4,27]],"date-time":"2020-04-27T00:06:31Z","timestamp":1587945991000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jac\/article\/75\/Supplement_1\/i60\/5824460"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4,1]]},"references-count":22,"journal-issue":{"issue":"Supplement_1","published-online":{"date-parts":[[2020,4,21]]},"published-print":{"date-parts":[[2020,4,1]]}},"URL":"https:\/\/doi.org\/10.1093\/jac\/dkaa084","relation":{},"ISSN":["0305-7453","1460-2091"],"issn-type":[{"type":"print","value":"0305-7453"},{"type":"electronic","value":"1460-2091"}],"subject":[],"published-other":{"date-parts":[[2020,4]]},"published":{"date-parts":[[2020,4,1]]}}}